Biotech Industry Examiner

Menu
Menu
subscribe now
Search
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)

EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)

European biotech received a confidence boost as the EU’s European

Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

BioArctic, a Swedish biotechnology company renowned for its innovative approach

The explainable aging clock regulators might actually like

The explainable aging clock regulators might actually like

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause

Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause

Galapagos quits cell therapy. Europe’s CGT reckoning begins.

Galapagos quits cell therapy. Europe’s CGT reckoning begins.

The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech

The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech

MOST POPULAR

News

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top